Evaluation of the Childhood Hodgkin International Prognostic Score (CHIPS) in High-Risk Pediatric Hodgkin Lymphoma Patients Treated on Children's Oncology Group AHOD1331., PMID:40515508
Tight competition for the first line treatment of Hodgkin's lymphoma: a comprehensive review of practice-changing developments in recent years., PMID:40506833
Treatment of older patients with Hodgkin lymphoma., PMID:40504313
Case Report: Vanishing bile duct syndrome in Hodgkin's lymphoma: a case highlighting jaundice and lymphadenopathy as early clues., PMID:40469301
Final results of a multicentre pilot study evaluating brentuximab vedotin with cyclophosphamide, doxorubicin, etoposide and prednisone (BV-CHEP) for the treatment of aggressive adult T-cell leukaemia/lymphoma., PMID:40459047
Adverse cardiac events associated with antibody drug conjugates in cancer patients: a retrospective analysis on the FAERS database and randomized controlled trials., PMID:40455883
Primary Cutaneous Gamma-Delta T-Cell Lymphoma Presenting With Hemophagocytic Lymphohistiocytosis in a Young Polynesian Male., PMID:40452922
Postmarketing surveillance of brentuximab vedotin for previously untreated Hodgkin lymphoma in Japanese patients., PMID:40451861
Clinical Features and Outcomes of Primary Cutaneous Peripheral T-Cell Lymphoma, Not Otherwise Specified, Treated with CHOP-Based Regimens., PMID:40427170
Signal mining and analysis of adverse events of Brentuximab Vedotin base on FAERS and JADER databases., PMID:40378127
Improved efficacy of concurrent anti-PD1 antibody plus AVD versus ABVD in patients with newly diagnosed early unfavorable and advanced stage classic Hodgkin lymphoma: a retrospective matched cohort study., PMID:40372486
Assessment of the Tolerability and Optimal Dosing of the Combination of Brentuximab Vedotin and Lenalidomide in Patients With Relapsed or Refractory T-cell Lymphoma: Results of a Single-centre Phase 1 Dose-escalation Study., PMID:40364805
Anaplastic large cell lymphoma in children and adolescents., PMID:40351161
[Breast implant-associated anaplastic large cell lymphoma that developed 20 years after breast reconstruction and was successfully treated with chemotherapy]., PMID:40350275
Lee HJ, Ramchandren R, Friedman J, et al. Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphoma. Blood. 2025;145(3):290-299., PMID:40338570
Selecting appropriate therapy for cutaneous T-cell lymphomas (CTCLs): recent advances and the unmet need., PMID:40336318
[Not Available]., PMID:40330314
Nivolumab plus ifosfamide, carboplatin, and etoposide are a highly effective first salvage regimen in high-risk relapsed/refractory Hodgkin lymphoma., PMID:40313510
Brentuximab Vedotin and Nivolumab for Untreated Patients with Hodgkin Lymphoma: Long-term Results., PMID:40311072
Fatal mycosis fungoides, misdiagnosed as contact dermatitis., PMID:40307495
Versatile intact LC-MS method for evaluating the drug-antibody ratio and drug load distribution of antibody-drug conjugates in human plasma., PMID:40267607
Outcomes of patients with Hodgkin lymphoma receiving Brentuximab Vedotin (BV) as maintenance therapy after ASCT according to previous exposure to BV. A retrospective analysis of the EBMT Lymphoma Working Party in collaboration with GELTAMO, FIL, LYSA, and Turkish Lymphoma Group., PMID:40234724
Nodal Peripheral T-Cell Lymphoma: Therapeutic Challenges and Future Perspectives., PMID:40227698
Retreatment with Brentuximab Vedotin in Patients with Relapsed/Refractory CD30+ Malignancies: A Retrospective Medical Chart Review Study in Spain-The BELIEVE Study., PMID:40227660
Advancements in targeting CD30 for lymphoma therapy: a historical perspective and future directions., PMID:40227173
Drug-induced Guillain-Barré Syndrome: a disproportionality analysis based on the US FDA adverse event reporting system., PMID:40220275
Molecular heterogeneity of CD30+ peripheral T-cell lymphoma with prognostic significance and therapeutic implications: a retrospective multi-centre study., PMID:40215750
Mycosis Fungoides With Small Bowel Involvement Successfully Treated With Brentuximab Vedotin., PMID:40202238
Real-world outcomes of brentuximab vedotin as consolidation therapy after autologous stem cell transplantation in relapsed/refractory Hodgkin lymphoma: A systematic review and meta-analysis., PMID:40200006
Acute Generalized Exanthematous Pustulosis in a Patient Treated With Bendamustine-Brentuximab Vedotin., PMID:40197101
Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial., PMID:40186077
Bendamustine supercharge plus brentuximab vedotin as early salvage therapy following failure to obtain complete metabolic remission after two cycles of adriamycin-bleomycin-vinblastine-dacarbazine for classic Hodgkin lymphoma in patients aged ≤ 60 years: Long-term efficacy results of a retrospective multicentre study., PMID:40176291
Next-generation sequencing guides diagnosis and treatment in a complex presentation of ALK-positive anaplastic large-cell lymphoma: a case report., PMID:40161372
Outcomes in patients with classic Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: a real world analysis from 15 U.S. academic centers., PMID:40140364
Therapeutic advances for Cutaneous T Cell Lymphoma., PMID:40131851
Brentuximab vedotin monotherapy is a feasible and effective treatment for older patients with classical Hodgkin lymphoma unsuitable for curative chemotherapy: Results from the prospective GHSG-NLG phase II BVB trial., PMID:40124718
Hodgkin lymphoma presenting as paraneoplastic cerebellar degeneration: A case report., PMID:40115791
Optimizing Brentuximab Vedotin Dosing in Pediatric Patients with Advanced Hodgkin Lymphoma: A Population Pharmacokinetic and Exposure-Response Analysis., PMID:40095373
Systemic Targeted Therapies in Patients with Relapsed/Refractory Advanced Stage Cutaneous T-cell Lymphoma: A Real-world Single-centre Case Series., PMID:40079767
Central nervous system relapse of primary cutaneous anaplastic large cell lymphoma: A case report., PMID:40052018
Retrospective Evaluation of Clinical and Follow-Up Outcomes in Primary Cutaneous CD30+ Lymphoproliferative Disorders., PMID:40045743
Gastrointestinal toxicity of antibody-drug conjugates: a pharmacovigilance study using the FAERS database., PMID:40033454
Current Issues and Future Perspectives of Targeted Therapies in Primary Mediastinal Large B-Cell Lymphoma., PMID:40004722
Combination of Brentuximab Vedotin and Pembrolizumab as Salvage Treatment Before Autologous Stem Cell Transplantation and Maintenance in Patients with Relapsed/Refractory Hodgkin Lymphoma., PMID:40002670
Pneumocystis jirovecii pneumonia with use of brentuximab vedotin in treatment-naïve Hodgkin lymphoma., PMID:39992225
Hodgkin Lymphoma Treatment With Brentuximab Vedotin in a Patient With HIV, Liver Failure, and Anemia Without Transfusion., PMID:39944794
Antibody-Drug Conjugates Targeting CD30 in T-Cell Lymphomas: Clinical Progression and Mechanism., PMID:39941862
Alectinib combined with VRCD and BV monoclonal antibody for the treatment of ALK-positive large B-cell lymphoma: a case report and literature review., PMID:39906668
Classic Hodgkin lymphoma: Pathobiological features that impact emerging therapies., PMID:39904647
Retreatment with brentuximab vedotin for discordant peripheral T-cell lymphomas., PMID:39896719
For research use only. Not for human or drug use.
